Quick Answer
Maze Therapeutics, Inc. reported R&D Expense of $108.45 million for fiscal year 2025.
Maze Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $108.45M | +29.9% |
| 2024 | $83.50M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.19M | +26.9% | -10.4% |
| June 30, 2025 | $28.11M | +43.8% | +1.9% |
| March 31, 2025 | $27.58M | +26.1% | +38.9% |
| September 30, 2024 | $19.86M | — | +1.6% |
| June 30, 2024 | $19.55M | — | -10.7% |
| March 31, 2024 | $21.88M | — | — |
- Maze Therapeutics, Inc. showed an increase of +29.9% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Maze Therapeutics, Inc.’s r&d expense has grown by 29.9% (from $83.50 million to $108.45 million).
- The most recent figure is from Maze Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: